Recommended guidelines for diagnosis and treatment of postmenopausal osteoporosis;Doporučené postupy pro diagnostiku a terapii postmenopauzální osteoporózy

Osteologicky Bulletin

Volumn 8, Issue 1, 2003, Pages 8-13

  Bayer, M ^b   Blahos J ^b   Broulik P ^b   Dolecek R ^b   Donat J ^b   Havelka, S ^b   Kasalicky P ^b   Kutilek S ^b   Palička, Vladimir ^a   Stepan J ^b   Trnavsky K ^b   Vyskocil V ^b   Wilczek, H ^b  

^a UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CALCITONIN; FLUORIDE; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

BONE DENSITY; BONE MINERAL; DENSITOMETRY; DIAGNOSTIC IMAGING; DUAL ENERGY X RAY ABSORPTIOMETRY; HUMAN; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; REVIEW;

EID: 0038555600     PISSN: 12113778     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Anonymous: Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. Vol. 843. Geneva: World Health Organisation, 1994.
2. Black DM, Palermo L, Nevitt MC et al. Defining incident vertebral deformity: a prospective comparison of several approaches. The Study of Osteoporotic Fractures Research Group. J Bone Miner Res 1999;14:90-101.
3. Black DM, Thompson DE, Bauer DC et al (FIT Research Group). Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. J Clin Endocrinol Metab 2000;85:4118-4124.
4. Brown JP, Josse RG, Canada TSACotOSo. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002;12,Suppl.10: 1-33.
5. Cadarette SM, Jaglal SB, Murray TM et al. Evaluation of decision rules for referring women for bone densitometry by dual-energy x-ray absorptiometry. JAMA 2001;286:57-63.
6. Campbell AJ, Robertson MC, Gardner MM et al. Randomized controlled trial of a general practice programme of home based exercise to prevent falls in elderly women. BMJ 1997;315:1065-1069.
7. Chrischilles EA, Butler CD, Davis CS et al. A model of lifetime osteoporosis impact [published erratum appears in Arch Intern Med 1922 Mar; 152(3):655]. Arch Intern Med 1991;151:2026-32.
8. Close J, Ellis M, Hooper R et al. Prevention of falls in the elderly trial (PROFET): a randomized controlled trial. Lancet 1999;353:93-97.
9. Cummings SR, Black DM, Nevitt MC et al. Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group [see comments]. Lancet 1993;341:72-5.
10. Cummings SR, Nevitt MC, Browner WS et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1995; 332:767-73.
11. Dargent Molina P, Favier F, Grandjean H et al. Fall-related factors and risk of hip fracture: the EPIDOS prospective study. Lancet 1996;348:145-9.
12. Delmas PD, Eastell R, Garnero P et al. The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporosis Int 2000;11,Suppl.6:2-17.
13. Faulkner KG, McClung MR. Quality control of DXA instruments in multicenter trials. Osteoporosis Int 1995;5:218-27.
14. Harris ST, Watts NB, Genant HK et al (Vertebral Efficacy with Risedronate Therapy [VERT] Study Group). Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 1999;282:1344-1352.
15. Hodgson SF, Watts NB, Bilezikian JP et al. American Association of Clinical Endocrinologists 2001 Medical Guidelines for Clinical Practice for the Prevention and Management of Postmenopausal Osteoporosis. Endocr Pract 2001;7:293-312.
16. Kanis JA, Gluer CC. An update on the diagnosis and assessment of osteoporosis with densitometry. Committee of Scientific Advisors, International Osteoporosis Foundation. Osteoporosis Int 2000;11:192-202.
17. Kanis JA, Johnell O, Oden A et al. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 2001;12:989-95.
18. Klotzbuecher CM, Ross PD, Landsman PB et al. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 2000;15:721-39.
19. Liberman UA, Weiss SR, Broll J et al (Alendronate Phase III Osteoporosis Treatment Study Group). Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333: 1437-1443.
20. Lindsay R, Cosman F, Lobo RA et al. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial. J Clin Endocrinol Metab 1999;84:3076-3081.
21. Lindsay R, Silverman SL, Cooper C et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001;285:320-3.
22. Lowe CE, Depew WT, Vanner SJ et al. Upper gastrointestinal toxicity of alendronate. Am J Gastroenterol 2000;95:634-640.
23. MacKelvie KJ, McKay HA, Petit MA et al. Bone mineral responses to a 7 month randomized controlled, school-based jumping intervention in 121 prepubertal boys: associations with ethnicity and body mass index. J Bone Miner Res 2002;17: 834-844.
24. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996;312:1254-9.
25. McClung MR, Geusens P, Miller PD et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001;344:333-40.
26. Melton LJ, Atkinson EJ, O'Connor MK et al. Bone density and fracture risk in men. J Bone Miner Res 1998;13:1915-23.
27. Melton LJ, Atkinson EJ, Cooper C et al. Vertebral fractures predict subsequent fractures. Osteoporosis Int 1999;10:214-21.
28. NIH Consensus Development Panel on Osteoporosis Prevention D, Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285:785-95.
29. Petit MA, McKay HA, MacKelvie KJ et al. A randomized school-based jumping intervention confers site and maturity-specific benefits on bone structural properties in girls: a hip structural analysis study. J Bone Miner Res 2002;17:363-372.
30. Pols HA, Felsenberg D, Hanley DA et al (Fosamax International Trial Study Group). Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Osteoporosis Int 1999;9:461-468.
31. Ravn P, Overgaard K, Huang C et al. Comparison of bone densitometry of the phalanges, distal forearm and axial skeleton in early postmenopausal women participating in the EPIC Study. Osteoporos Int 1996;6:308-13.
32. Ravn P, Weiss SR, Rodriguez-Portales JA et al (Alendronate Osteoporosis Prevention Study Group). Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. J Clin Endocrinol Metab 2000; 85:1492-1497.
33. Reginster J, Minne HW, Sorensen OH et al (Vertebral Efficacy with Risedronate Therapy [VERT] Study Group). Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporosis Int 2000;11:83-91.
34. Riggs BL, Melton LJ. Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density. J Bone Miner Res 2002;17:11-4.
35. Rosenthall L, Caminis J, Tenehouse A. Calcaneal ultrasonometry: response to treatment in comparison with dual x-ray absorptiometry measurements of the lumbar spine and femur. Calcif Tissue Int 1999;64:200-4.
36. Ross P, Huang C, Davis J et al. Predicting vertebral deformity using bone densitometry at various skeletal sites and calcaneus ultrasound. Bone 1995;16:325-32.
37. Schnitzer T, Bone HG, Crepaldi G et al (Alendronate Once-Weekly Study Group). Therapeutic equivalence of alendronate 70mg once-weekly and alendronate 10mg daily in the treatment of osteoporosis. Aging 2000;12:1-12.
38. Stepan J, Havelka S, Kamberská Z, Bernátová M. Epidemiologie der Osteoporose in der Tschechischen Republik. J Mineralstoffwechsel 2002;9:7-13.
39. Stock JL, Bell NH, Chesnut CH III et al. Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women. Am J Med 1997;103: 291-297.
40. Tonino RP, Meunier PJ, Emkey R et al (Phase III Osteoporosis Treatment Study Group). Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. J Clin Endocrinol Metab 2000;85:3109-3115.
41. Torgerson DJ, Campbell MK, Thomas RE, Reid DM. Prediction of perimenopausal fractures by bone mineral density and other risk factors. J Bone Miner Res 1996; 11:293-7.
42. Van Haastregt JC, Diederiks JP, van Rossum E et al. Effects of a programme of multifactorial home visits on falls and mobility impairments in elderly people at risk: a randomized controlled trial. BMJ 2000;321:994-998.
43. Van Staa TP, Leufkens HG, Abenhaim L et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000;15:993-1000.
44. Wolff I, Van Croonenborg JJ, Kemper HCG et al. The effect of exercise training programs on bone mass: A meta-analysis of published controlled trials in pre- and postmenopausal women. Osteoporosis Int 1999;9:1-12.
45. Woodhouse A, Black DM. BMD at various sites for the prediction of hip fractures: a meta analysis. J Bone Miner Res 2000;15,Suppl.1:145